Literature DB >> 30589919

Treatment of Metastatic Prostate Cancer in 2018.

Chung-Han Lee1, Philip Kantoff2.   

Abstract

Entities:  

Mesh:

Year:  2019        PMID: 30589919      PMCID: PMC6597329          DOI: 10.1001/jamaoncol.2018.5621

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN: 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  10 in total

1.  DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.

Authors:  Joaquin Mateo; Suzanne Carreira; Shahneen Sandhu; Susana Miranda; Helen Mossop; Raquel Perez-Lopez; Daniel Nava Rodrigues; Dan Robinson; Aurelius Omlin; Nina Tunariu; Gunther Boysen; Nuria Porta; Penny Flohr; Alexa Gillman; Ines Figueiredo; Claire Paulding; George Seed; Suneil Jain; Christy Ralph; Andrew Protheroe; Syed Hussain; Robert Jones; Tony Elliott; Ursula McGovern; Diletta Bianchini; Jane Goodall; Zafeiris Zafeiriou; Chris T Williamson; Roberta Ferraldeschi; Ruth Riisnaes; Bernardette Ebbs; Gemma Fowler; Desamparados Roda; Wei Yuan; Yi-Mi Wu; Xuhong Cao; Rachel Brough; Helen Pemberton; Roger A'Hern; Amanda Swain; Lakshmi P Kunju; Rosalind Eeles; Gerhardt Attard; Christopher J Lord; Alan Ashworth; Mark A Rubin; Karen E Knudsen; Felix Y Feng; Arul M Chinnaiyan; Emma Hall; Johann S de Bono
Journal:  N Engl J Med       Date:  2015-10-29       Impact factor: 91.245

2.  Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.

Authors:  Matthew R Smith; Fred Saad; Simon Chowdhury; Stéphane Oudard; Boris A Hadaschik; Julie N Graff; David Olmos; Paul N Mainwaring; Ji Youl Lee; Hiroji Uemura; Angela Lopez-Gitlitz; Géralyn C Trudel; Byron M Espina; Youyi Shu; Youn C Park; Wayne R Rackoff; Margaret K Yu; Eric J Small
Journal:  N Engl J Med       Date:  2018-02-08       Impact factor: 91.245

3.  Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer.

Authors:  Maha Hussain; Karim Fizazi; Fred Saad; Per Rathenborg; Neal Shore; Ubirajara Ferreira; Petro Ivashchenko; Eren Demirhan; Katharina Modelska; Andrew Krivoshik; Cora N Sternberg
Journal:  N Engl J Med       Date:  2018-06-28       Impact factor: 91.245

4.  Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making.

Authors:  Wassim Abida; Joshua Armenia; Anuradha Gopalan; Ryan Brennan; Michael Walsh; David Barron; Daniel Danila; Dana Rathkopf; Michael Morris; Susan Slovin; Brigit McLaughlin; Kristen Curtis; David M Hyman; Jeremy C Durack; Stephen B Solomon; Maria E Arcila; Ahmet Zehir; Aijazuddin Syed; Jianjiong Gao; Debyani Chakravarty; Hebert Alberto Vargas; Mark E Robson; Vijai Joseph; Kenneth Offit; Mark T A Donoghue; Adam A Abeshouse; Ritika Kundra; Zachary J Heins; Alexander V Penson; Christopher Harris; Barry S Taylor; Marc Ladanyi; Diana Mandelker; Liying Zhang; Victor E Reuter; Philip W Kantoff; David B Solit; Michael F Berger; Charles L Sawyers; Nikolaus Schultz; Howard I Scher
Journal:  JCO Precis Oncol       Date:  2017-05-31

5.  Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.

Authors:  Nicholas D James; Johann S de Bono; Melissa R Spears; Noel W Clarke; Malcolm D Mason; David P Dearnaley; Alastair W S Ritchie; Claire L Amos; Clare Gilson; Rob J Jones; David Matheson; Robin Millman; Gerhardt Attard; Simon Chowdhury; William R Cross; Silke Gillessen; Christopher C Parker; J Martin Russell; Dominik R Berthold; Chris Brawley; Fawzi Adab; San Aung; Alison J Birtle; Jo Bowen; Susannah Brock; Prabir Chakraborti; Catherine Ferguson; Joanna Gale; Emma Gray; Mohan Hingorani; Peter J Hoskin; Jason F Lester; Zafar I Malik; Fiona McKinna; Neil McPhail; Julian Money-Kyrle; Joe O'Sullivan; Omi Parikh; Andrew Protheroe; Angus Robinson; Narayanan N Srihari; Carys Thomas; John Wagstaff; James Wylie; Anjali Zarkar; Mahesh K B Parmar; Matthew R Sydes
Journal:  N Engl J Med       Date:  2017-06-03       Impact factor: 91.245

6.  Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial.

Authors:  Gwenaelle Gravis; Jean-Marie Boher; Florence Joly; Michel Soulié; Laurence Albiges; Franck Priou; Igor Latorzeff; Remy Delva; Ivan Krakowski; Brigitte Laguerre; Frédéric Rolland; Christine Théodore; Gael Deplanque; Jean-Marc Ferrero; Stéphane Culine; Loïc Mourey; Philippe Beuzeboc; Muriel Habibian; Stéphane Oudard; Karim Fizazi
Journal:  Eur Urol       Date:  2015-11-21       Impact factor: 20.096

7.  Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.

Authors:  Karim Fizazi; NamPhuong Tran; Luis Fein; Nobuaki Matsubara; Alfredo Rodriguez-Antolin; Boris Y Alekseev; Mustafa Özgüroğlu; Dingwei Ye; Susan Feyerabend; Andrew Protheroe; Peter De Porre; Thian Kheoh; Youn C Park; Mary B Todd; Kim N Chi
Journal:  N Engl J Med       Date:  2017-06-04       Impact factor: 91.245

8.  Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.

Authors:  Nicholas D James; Matthew R Sydes; Noel W Clarke; Malcolm D Mason; David P Dearnaley; Melissa R Spears; Alastair W S Ritchie; Christopher C Parker; J Martin Russell; Gerhardt Attard; Johann de Bono; William Cross; Rob J Jones; George Thalmann; Claire Amos; David Matheson; Robin Millman; Mymoona Alzouebi; Sharon Beesley; Alison J Birtle; Susannah Brock; Richard Cathomas; Prabir Chakraborti; Simon Chowdhury; Audrey Cook; Tony Elliott; Joanna Gale; Stephanie Gibbs; John D Graham; John Hetherington; Robert Hughes; Robert Laing; Fiona McKinna; Duncan B McLaren; Joe M O'Sullivan; Omi Parikh; Clive Peedell; Andrew Protheroe; Angus J Robinson; Narayanan Srihari; Rajaguru Srinivasan; John Staffurth; Santhanam Sundar; Shaun Tolan; David Tsang; John Wagstaff; Mahesh K B Parmar
Journal:  Lancet       Date:  2015-12-21       Impact factor: 79.321

9.  Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol.

Authors:  M R Sydes; M R Spears; M D Mason; N W Clarke; D P Dearnaley; J S de Bono; G Attard; S Chowdhury; W Cross; S Gillessen; Z I Malik; R Jones; C C Parker; A W S Ritchie; J M Russell; R Millman; D Matheson; C Amos; C Gilson; A Birtle; S Brock; L Capaldi; P Chakraborti; A Choudhury; L Evans; D Ford; J Gale; S Gibbs; D C Gilbert; R Hughes; D McLaren; J F Lester; A Nikapota; J O'Sullivan; O Parikh; C Peedell; A Protheroe; S M Rudman; R Shaffer; D Sheehan; M Simms; N Srihari; R Strebel; S Sundar; S Tolan; D Tsang; M Varughese; J Wagstaff; M K B Parmar; N D James
Journal:  Ann Oncol       Date:  2018-05-01       Impact factor: 32.976

10.  Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial.

Authors:  Christos E Kyriakopoulos; Yu-Hui Chen; Michael A Carducci; Glenn Liu; David F Jarrard; Noah M Hahn; Daniel H Shevrin; Robert Dreicer; Maha Hussain; Mario Eisenberger; Manish Kohli; Elizabeth R Plimack; Nicholas J Vogelzang; Joel Picus; Matthew M Cooney; Jorge A Garcia; Robert S DiPaola; Christopher J Sweeney
Journal:  J Clin Oncol       Date:  2018-01-31       Impact factor: 50.717

  10 in total
  5 in total

1.  Prediction of Synergistic Drug Combinations for Prostate Cancer by Transcriptomic and Network Characteristics.

Authors:  Shiqi Li; Fuhui Zhang; Xiuchan Xiao; Yanzhi Guo; Zhining Wen; Menglong Li; Xuemei Pu
Journal:  Front Pharmacol       Date:  2021-04-12       Impact factor: 5.810

Review 2.  Nanovectorization of Prostate Cancer Treatment Strategies: A New Approach to Improved Outcomes.

Authors:  Kenneth Omabe; Clément Paris; François Lannes; David Taïeb; Palma Rocchi
Journal:  Pharmaceutics       Date:  2021-04-21       Impact factor: 6.321

3.  Calcium cytotoxicity sensitizes prostate cancer cells to standard-of-care treatments for locally advanced tumors.

Authors:  Alessandro Alaimo; Marco Lorenzoni; Paolo Ambrosino; Arianna Bertossi; Alessandra Bisio; Alice Macchia; Eugenio Zoni; Sacha Genovesi; Francesco Cambuli; Veronica Foletto; Dario De Felice; Maria Virginia Soldovieri; Ilaria Mosca; Francesco Gandolfi; Matteo Brunelli; Gianluca Petris; Anna Cereseto; Alvaro Villarroel; George Thalmann; Francesco Giuseppe Carbone; Marianna Kruithof-de Julio; Mattia Barbareschi; Alessandro Romanel; Maurizio Taglialatela; Andrea Lunardi
Journal:  Cell Death Dis       Date:  2020-12-07       Impact factor: 8.469

4.  Longitudinal CTCs gene expression analysis on metastatic castration-resistant prostate cancer patients treated with docetaxel reveals new potential prognosis markers.

Authors:  Thais Pereira-Veiga; Miriam González-Conde; Luis León-Mateos; Roberto Piñeiro-Cid; Carmen Abuín; Laura Muinelo-Romay; Mónica Martínez-Fernández; Jenifer Brea Iglesias; Jorge García González; Urbano Anido; Santiago Aguín-Losada; Víctor Cebey; Clotilde Costa; Rafael López-López
Journal:  Clin Exp Metastasis       Date:  2021-02-26       Impact factor: 5.150

5.  An Integrative Multi-Omics Analysis Based on Nomogram for Predicting Prostate Cancer Bone Metastasis Incidence.

Authors:  Jun Zhao; Rui Wang; Xiaoxin Sun; Kai Huang; Jiacheng Jin; Lan Lan; Yuli Jian; Zhongyang Xu; Haotian Wu; Shujing Wang; Jianbo Wang
Journal:  Genet Res (Camb)       Date:  2022-09-29       Impact factor: 1.375

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.